GB1072414A — New dihydrothieno(3,2-d)pyrimidines

USPTO Abstract

The invention comprises compounds of the Formula I wherein R represents an unsubstituted amino group; R1 represents a hydroxy group substituted by a (C1- 5 alkoxy)-C1- 5 alkyl group, an alkylmercapto group, an unsubstituted amino group or an alkyl, alkenyl, formula -NR3R4 (in which R3 represents an unsubstituted amino group or an alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl or a dialkylaminoalkyl group of not more than 10 carbon atoms or an aralkyl or cycloalkyl group and R4 represents a hydrogen atom or an alkyl or hydroxyalkyl group of not more than 10 carbon atoms or R3 and R4 together with the adjacent nitrogen atom represent a heterocyclic group which may contain a further hetero atom and which may be substituted by a C1- 3 alkyl group); R2 represents a methyl group and n represents 0 or 1, and non-toxic acid addition salts thereof, and the preparation thereof by reacting a compound of the Formula II, wherein one of A and A1 represents a halogen atom or a free or C1- 5 alkyl substituted mercapto group and the other (if not representing a halogen atom or a free or C1- 5 alkyl substituted mercapto group) represents any of the groups which may be represented by R and R1 respectively, with a compound of the formula RH (where A represents a halogen atom or a free or C1- 5 alkyl substituted mercapto group) and/or R1H (where A1 represents a halogen atom or a free or C1- 5 alkyl substituted mercapto group), and, if desired, converting the product into a non-toxic acid addition salt thereof. <FORM:1072414/C2/1> 2 - Chloro - 4 - morpholino - dihydrothieno-[3,2-d]pyrimidin may be prepared by the action of morpholine on 2,4-dichloro-dihydrothieno[3,2-d]pyrimidine. Therapeutic compositions, which have cardiovascular, sedative, diuretic, cytostatic, bacteriostatic, antiphlogistic and/or anti-pyretic activities, and which may take the forms of capsules, dragees, powders, drop solutions, suspensions, solutions, ampoules and suppositories, for oral, parenteral and topical application, comprise compounds of the Formula I or their non-toxic acid addition salts together with a pharmaceutical carrier.